Insiders Trades
Patterson Companies, Inc. Stock: price and insider trades · United States
Patterson Companies, Inc.: what insiders have been doing
This page follows insider dealings at Patterson Companies, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Saint Paul, United States. The group dates from 1877. Nothing new has been filed by managers of Patterson Companies, Inc. in twelve months, the latest record being from 17 April 2025.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
131
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€3M
28 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended April 2024 · cache
Income statement
RevenueUS$5.7B
Gross profitUS$1.2B21% margin
Net incomeUS$160.1M2.8% margin
Last declaration on 17 April 2025
Declarations131 total
10,624 shares0Common StockSEC:0000950170-25-055155:0
9,807 shares0Common StockSEC:0000950170-25-055153:0
20,840 shares0Common StockSEC:0000950170-25-055158:0
5,186 shares0Common StockSEC:0000950170-25-055149:0
4,577 shares0Common StockSEC:0000950170-25-055146:0
12,788 sharesCommon StockSEC:0000950170-25-055176:0
7,820 sharesCommon StockSEC:0000950170-25-055222:0
56,145 sharesCommon StockSEC:0000950170-25-055193:0
92,869 sharesCommon StockSEC:0000950170-25-055185:0
48,788 sharesCommon StockSEC:0000950170-25-055209:0
18,114 sharesCommon StockSEC:0000950170-25-055205:0
38,242 sharesCommon StockSEC:0000950170-25-055202:0
41,300 sharesCommon StockSEC:0000950170-25-055181:0
807 shares@ US$31.082.8% of flowCommon StockSEC:0000950170-24-137424:0
420 shares@ US$31.081.3% of flowCommon StockSEC:0000950170-24-137192:0
5,374 shares@ US$22.833.7% of flowCommon StockSEC:0000950170-24-134653:0
1,052 shares@ US$20.761.2% of flowCommon StockSEC:0000950170-24-126404:0
939 shares@ US$20.761.9% of flowCommon StockSEC:0000950170-24-126413:0
9 shares@ US$18.5640.2% of flowCommon StockSEC:0000950170-24-112595:0
7,820 shares@ US$21.7422.6% of flowCommon StockSEC:0000950170-24-107700:0
7,820 shares@ US$21.7422.6% of flowCommon StockSEC:0000950170-24-107716:0
7,820 shares@ US$21.7422.6% of flowCommon StockSEC:0000950170-24-107696:0
7,820 shares@ US$21.7422.6% of flowCommon StockSEC:0000950170-24-107704:0
7,820 shares@ US$21.7453.1% of flowCommon StockSEC:0000950170-24-107686:0
7,820 shares@ US$21.74100.0% of flowCommon StockSEC:0000950170-24-107721:0
25 of 131 declarations
About Patterson Companies, Inc.
Patterson Companies, Inc. is a U.S.-listed healthcare distribution and services company traded on the NASDAQ under the ticker PDCO. For international investors, it is a long-established but relatively niche participant in the North American healthcare supply chain, focused on dental and animal health customers. The company is headquartered in Saint Paul, Minnesota, and its operating model is built around logistics, field sales, product availability, and customer support rather than high-margin branded manufacturing. Patterson positions itself as a partner to dental practices and veterinary professionals by combining products, technology, and service capabilities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000089102424000008/pdco-20240427.htm?utm_source=openai))
Patterson’s roots date back to the nineteenth century, and over time it evolved into a two-segment business: Patterson Dental and Patterson Animal Health. The dental business serves dentists and dental clinics with equipment, consumables, instruments, digital solutions, and related services. The animal health business supplies veterinarians and animal health professionals with pharmaceuticals, consumables, equipment, and operational support tools. This dual-market structure gives Patterson exposure to end markets that are generally resilient and recurring, but still highly competitive. The company competes against specialized distributors, direct manufacturers, and increasingly digital or e-commerce channels, which keeps pricing discipline and service quality important to the investment case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000089102424000008/pdco-20240427.htm?utm_source=openai))
Read moreShow less
Geographically, Patterson has a broad footprint across North America, particularly the United States and Canada, and it also serves parts of the U.K. through its animal health activities. Its competitive edge is not based on scale alone; it comes from distribution breadth, customer relationships, technical sales coverage, and added-value services that help practices run more efficiently. At the same time, this model carries exposure to supplier concentration, margin pressure, logistics execution, and the ongoing shift toward online purchasing and private-label or direct-to-customer alternatives. Recent company commentary has emphasized operational discipline, product innovation, and customer support across both end markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000119312524208250/d888887dex99.htm?utm_source=openai))
Recent developments have been especially important. In December 2024, Patterson announced a definitive merger agreement with Patient Square Capital, under which the private equity firm would acquire Patterson for $31.35 per share in an all-cash deal valued at roughly $4.1 billion, including refinancing of receivables facilities. During fiscal 2025, the company also highlighted the impact of a cybersecurity-related disruption tied to Change Healthcare on earnings, while continuing to return cash to shareholders through dividends and share repurchases. In early 2025, Patterson reported quarterly results showing softer sales trends but continued focus on execution while progressing toward the proposed transaction. For investors, the current story is therefore a mix of stable end-market exposure, moderate operating pressure, and a major corporate event that could redefine the stock’s future. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000089102425000003/pdco-20250125.htm?utm_source=openai))
